
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is attractive fundamentally because Yartemlea has shown a strong U.S. launch, with 2Q sales of $28.5M, 74 unique ordering accounts, and about 75% of orders coming from adults, suggesting broadening adoption rather than a narrow early pull-forward. The company’s outlook is further supported by reimbursement tailwinds from the permanent J-code and NTAP, which should reduce friction and improve hospital economics, while physician feedback points to roughly 30% to 35%+ market penetration and about $400M in peak sales even with almost no Europe contribution. Although the negative CHMP opinion is a near-term overhang, the market appears to assign limited European value already, so a reversal or partnership would be incremental upside on top of a still-compelling U.S. growth story.
Bears say
Omeros is highly exposed to binary clinical and regulatory outcomes, with narsoplimab representing the near-term value driver and the company already facing a negative CHMP opinion in Europe for TA-TMA. The setback increases uncertainty around approval and commercialization, while competition from larger, better-resourced biotech peers further weakens its ability to convert pipeline progress into durable profitability. The negative outlook is reinforced by rising go-forward R&D spend, a lower exit multiple, and a risk-adjusted DCF that now uses a 13.1% WACC, reflecting material regulatory, clinical, commercialization, and development risk.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Omeros (OMER) Forecast
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares